Trastuzumab binds HER2 on target cells and its Fc engages FcγR-bearing immune cells (e.g., NK cells) to mediate antibody‑dependent cellular cytotoxicity (ADCC), killing HER2+ cells; it may also trigger complement and inhibit survival signaling.